Neoadjuvant Dose-dense Gemcitabine and Cisplatin in Muscle-invasive Bladder Cancer: Results of a Phase 2 Trial.

ABSTRACT:

Background

Accelerated (also termed dose-dense, DD) chemotherapy regimens such as accelerated methotrexate, vinblastine, doxorubicin, and cisplatin have shown better efficacy and tolerability in the metastatic setting, and shortened the time to surgery in the neoadjuvant setting compared to standard-schedule regimens. We hypothesized that a DD schedule of gemcitabine and cisplatin (GC) would shorten the time to surgery and yield similar pathologic complete response rates (pT0) in patients with muscle-invasive bladder cancer (MIBC) compared with historical controls with standard GC.

Objective

To determine the safety and efficacy of neoadjuvant DDGC in MIBC.

Design setting and participants

Patients with cT2-4a, N0-1, M0 MIBC were eligible and received three 14-d cycles

SUBMITTER: Anari F 

PROVIDER: S-EPMC6226048 | biostudies-literature | 2018 May

REPOSITORIES: biostudies-literature